|
Los Angeles, CA – September 11, 2009 – Bison Capital announced that it has sold its security holdings in Metagenics, Inc, the leading manufacturer and distributor of science-based medical foods and nutraceuticals to licensed healthcare professionals worldwide. Metagenics entered into a strategic partnership with Alticor, an $8 billion global company with a shared commitment to innovative scientific research and development of quality products. Under the terms of the agreement entered into by the companies, Alticor acquired a substantial ownership interest in Metagenics and Bison sold its holdings.
Metagenics is a global life sciences company focused on reversing chronic illness and improving health. Founded in 1983, the company serves tens of thousands of health care professionals and more than a million patients throughout the world and holds more than 40 proprietary formula patents for use in nutraceuticals, medical foods, and pharmaceuticals. Today, Metagenics continues its leadership role through its world class sales force, by successfully merging the disciplines of nutritional genomics, functional medicine, and therapeutic lifestyle change programs to find solutions to society’s most pressing health concerns.
“We are thrilled with the achievements by Metagenics over the past four years” said Ping Chu, partner at Bison Capital. “The management team, under the leadership of Jeff Katke and Jeff Bland, did an outstanding job of delivering consistent, strong growth and building the infrastructure necessary to manage that growth, all the while maintaining their commitment to leading edge scientific research. The partnership with Alticor reflects the culmination of these efforts and positions the company to realize its vision of helping reverse chronic illness. For Bison, achieving a great outcome like this in the current economic environment reinforces our belief that our unique investment strategy is especially well suited to the lower middle market.”
Bison Capital makes growth equity investments
in middle-market companies, public or private, for expansion,
acquisitions or balance sheet restructuring. The firm’s
primary investment focus is partnering with entrepreneurs
and management teams seeking capital to grow their businesses.
|
